u/lina_novak

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

Keep every transaction hash in a note file with the order reference.

salma_baptista is right about confirmations. "Sent" is not a status.

ghost peak, check the plumbing first, it is always the plumbing

Two years at maintenance. The logistics are the only remaining work — ordering, storing, remembering.

Memo requirements are chain-specific. The chain you are describing does not use one.

Sent the same vial to VendorInvestigate and PeptideMeter. 97.7% against a claimed 97.0%. The difference was the gradient, not the material.

find the dose that holds, then stop optimising

nadia_trevino is right that stretching and reducing are different levers. Worth separating in every one of these threads.

Small fix — that is the network fee, not a supplier charge. The distinction matters for the complaint you are making.

a non-peptide agonist does not degrade the way a peptide does

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth les

Adding one thing — decide what maintenance looks like before you arrive at it.

Careful — you are treating retention time as identity. Two things can co-elute and the trace will not tell you.

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

Are you comparing doses across a small molecule and a peptide?

That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

Agreed. Network first, address second, amount third, and in that order every time.

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.

Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.

Has anyone here seen independent identity testing on this?

Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

Not convinced.

This is the point that should be at the top of every thread here. Identity first.

short peptides are cheap, which cuts both ways

you cannot report to two decimals off that baseline

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

Cosigning the wavelength point. Half the disagreements in this board are two people looking at different detectors.

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

phase 3 is where the comparison becomes fair

daily dosing, not weekly, so the exposure profile is different

the manufacturing story is genuinely different from the injectables

no clinical trial has established what these threads assert

Cosigning on planning it in advance. Deciding what maintenance looks like while still losing is much easier than deciding it in a panic.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

Dose reduction and interval extension are different interventions.

Agreed — and appetite is the leading indicator. The scale is the lagging one.

That is area percent, not mass percent. The trace cannot give you the second one.

Correction: that address format is not the chain you named. Worth checking before anybody follows this.